ABVC BioPharma, Inc.
NASDAQ Capital MarketTotal Valuation
ABVC BioPharma, Inc. carries a market capitalization of 24.29M, placing it among publicly traded companies globally. Its enterprise value stands at 44.07M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 24.29M |
| Enterprise Value | 44.07M |
Share Statistics
ABVC BioPharma, Inc. currently has 25.04M shares outstanding.
| Shares Outstanding | 25.04M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is -49.47, and the price-to-book ratio stands at 3.85.
| PE Ratio | N/A |
| PS Ratio | -49.47 |
| PB Ratio | 3.85 |
| P/TBV Ratio | 3.85 |
| P/FCF Ratio | -11.18 |
| P/OCF Ratio | -11.18 |
Enterprise Valuation
| EV / Sales | 38,090.86 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
ABVC BioPharma, Inc. maintains a current ratio of 0.07, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.37, indicating elevated leverage, while an interest coverage ratio of -43.94 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.07 |
| Quick Ratio | 0.05 |
| Debt / Equity | 21.37 |
| Debt / EBITDA | -0.38 |
| Interest Coverage | -43.94 |
Financial Efficiency
| Return on Equity (ROE) | -91.36 |
| Return on Assets (ROA) | -44.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 527.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
ABVC BioPharma, Inc.'s stock has declined approximately -69.66667% over the past 52 weeks. The 50-day moving average sits at 0.97, while the 200-day moving average is 1.31.
| Beta (5Y) | N/A |
| 52-Week Price Change | -69.66667% |
| 50-Day Moving Average | 0.97 |
| 200-Day Moving Average | 1.31 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, ABVC BioPharma, Inc. generated -795,950.00 in revenue and converted that into -7.90M in net income, yielding earnings per share of -0.34. EBITDA reached -6.82M, while operating income came in at -7.31M.
| Revenue | -795,950.00 |
| Gross Profit | -795,950.00 |
| Operating Income | -7.31M |
| Pretax Income | -8.40M |
| Net Income | -7.90M |
| EBITDA | -6.82M |
| EBIT | -7.31M |
| Earnings Per Share (EPS) | -0.34 |
Balance Sheet
ABVC BioPharma, Inc. holds 94,364.00 in cash and equivalents against 2.62M in total debt, resulting in a net debt position of 826,528.00. Total book value stands at 10.29M, with working capital of -5.28M providing operational flexibility.
| Cash & Cash Equivalents | 94,364.00 |
| Total Debt | 2.62M |
| Net Debt | 826,528.00 |
| Equity (Book Value) | 10.29M |
| Book Value Per Share | 0.41 |
| Working Capital | -5.28M |
Cash Flow
ABVC BioPharma, Inc. produced -3.52M in operating cash flow over the past twelve months.
| Operating Cash Flow | -3.52M |
| Capital Expenditures | N/A |
| Free Cash Flow | -3.52M |
| FCF Per Share | -0.14 |
Margins
ABVC BioPharma, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 918.55 and net profit margin of 992.85 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | 918.55 |
| Pretax Margin | 1,054.81 |
| Profit Margin | 992.85 |
| EBITDA Margin | 856.78 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5.66 |
| FCF Yield | -8.95 |
Stock Splits
ABVC BioPharma, Inc.'s most recent stock split took place on July 25, 2023 with a 10:1 split ratio.
| Last Split Date | 7/25/2023 |
| Split Ratio | 10:1 |
Scores
ABVC BioPharma, Inc. posts an Altman Z-Score of -4.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.00 |